Physician profile
Ananth Ranganathan
NPI 1497045306
$11,099.57
in general payments reported to CMS, 2019-2025
25 companies · $413 in 2025
The $413 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $2,292 · 2021: $6,575 · 2022: $503 · 2023: $607 · 2024: $559 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,219.23 | 2020-2021 | |
| Abbvie INC. | $433.84 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $413.14 | 2023-2025 | Myfembree |
| Pfizer INC. | $281.98 | 2021-2025 | |
| Astellas Pharma US INC | $211.11 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $193.65 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.12 | 2019-2024 | |
| Aspira Women'S Health INC | $181.74 | 2021-2022 | |
| Organon LLC | $163.92 | 2021-2025 | Nexplanon, Jada System |
| Merck Sharp & Dohme LLC | $146.74 | 2020-2023 | Gardasil 9 |
| Minerva Surgical, INC | $128.54 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $118.65 | 2022-2025 | |
| Hologic Sales and Service, LLC | $90.85 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Axsome Therapeutics, INC. | $54.36 | 2024 | Auvelity |
| Exeltis, USA INC. | $54.08 | 2022-2024 | Slynd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $39.77 | 2019-2021 | |
| Avion Pharmaceuticals | $27.01 | 2021 | |
| Ethicon US, LLC | $24.26 | 2019 | |
| Shield Therapeutics INC | $23.93 | 2023 | Accrufer |
| Biogen, INC. | $22.59 | 2025 | Zurzuvae |
| Allergan, INC. | $18.70 | 2019 | |
| Evofem Biosciences, INC. | $17.73 | 2022 | |
| Smith+Nephew, INC. | $17.64 | 2021 | |
| Coopersurgical, INC. | $17.62 | 2024 | Summit Doppler |
| Mylan Pharmaceuticals INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananth Ranganathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.